20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
00:03 , Aug 24, 2017 |  BC Extra  |  Preclinical News

Inhibiting PP2A reduces MECP2 in neuropsychiatric model

In a paper published in Science Translational Medicine , researchers showed that inhibiting protein phosphatase 2 ( PP2A ; PPP2CA) reduced levels of methyl CpG binding protein 2 ( MECP2 ; RTT), suggesting that modulating...
07:00 , Aug 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: TOR signaling pathway regulator (TIPRL); protein phosphatase 2 regulatory subunit A α (PPP2R1A)

Cancer INDICATION: Endometrial cancer Cell culture studies suggest inhibiting TIPRL could help treat PPP2R1A-mutant endometrial cancer. In a human PPP2R1A-mutant endometrial carcinoma cell line, shRNA targeting TIPRL - a binding partner of PPP2R1A - decreased...
07:00 , Sep 16, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer AT rich interactive domain 1A (ARID1A); protein phosphatase 2, regulatory subunit A a (PPP2R1A) A study in human tumor samples suggests that mutations...